Difference between revisions of "Ancillary testing in prostate cancer"

Ancillary testing in prostate cancer (view source)

1,249 bytes added , 15:18, 1 November 2022

no edit summary

48,475

edits

@@ Line 1: / Line 1: @@
 '''Ancillary testing in prostate cancer''' is evolving.  ''Prostate cancer panel'' redirect here.
+==PARP inhibitors==
+*Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref>
+Molecular panel:
+*[[BRCA1]].
+*[[BRCA2]].
+*ATM.
+*PALB2.
+==MMR testing==
+*MMR deficiency is seen in approximately 3% of prostate cancers.<ref>{{cite journal |authors=Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI |title=Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade |journal=JAMA Oncol |volume=5 |issue=4 |pages=471–478 |date=April 2019 |pmid=30589920 |pmc=6459218 |doi=10.1001/jamaoncol.2018.5801 |url=}}</ref>
 ==See also==
@@ Line 7: / Line 21: @@
 {{Reflist|1}}
-[[Category:Uropathology]]
+[[Category:Genitourinary pathology]]